Singla et al. found that CXCR4 inhibition slowed metastatic tumor growth in an advanced NSCLC model, reinforcing the potential of CXCR4-targeted therapies in controlling late-stage disease (Singla et al., 2015). Here, CXCR4 is linked to neoplasm.